OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Treatment Reviews is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review	269
Editorial Board	178
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming	144
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	119
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives	99
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors	96
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	95
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis	94
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in	83
Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis	82
The interplay of clonal hematopoiesis and cancer: Clinical implications in oncology	82
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer	79
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty	75
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis	71
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches	63
Proton therapy in breast cancer: bridging medical and radiation oncology	60
Editorial Board	59
De-escalation strategies with targeted therapies in non-small cell lung cancer	57
If it’s a target, it’s a pan-cancer target: Tissue is not the issue	57
Progress toward personalized management of stage II/III triple negative breast cancer	56
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications	55
Revisiting patient preference in resectable and irradiable stage III NSCLC in the immunotherapy era	54
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma	54
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment	54
Emerging antibody-based therapies for the treatment of acute myeloid leukemia	53

Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.	53
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	53
Optimizing care in early phase cancer trials: The role of palliative care	53
Editorial Board	52
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era	52
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?	51
Editorial Board	50
Uncertainties and controversies in axillary management of patients with breast cancer	50
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	49
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation	47
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?	47
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck	47
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment	47
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials	47
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy	46
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes	46
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation	46
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier	44
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations	44